Related Experiment Video

Updated: Aug 23, 2026

Intracellular Refolding Assay
07:18

Intracellular Refolding Assay

Published on: January 24, 2012

[Heat shock protein 70 binding protein 1 induces enhanced apoptotic response against anticancer drugs in tumor cells]

Susumu Tanimura1, Michiaki Kohno

  • 1Laboratory of Cell Regulation, Department of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 31, 2004
PubMed

Insights

Overexpressing Heat Shock Protein Binding Protein 1 (HspBP1) enhances tumor cell sensitivity to chemotherapy by inhibiting Hsp70 chaperone activity. This finding suggests Hsp70 inhibition boosts therapeutic efficacy.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Context:

  • Heat shock proteins (Hsps), including Hsp70/Hsc70, play crucial roles in cellular processes and can influence apoptosis.
  • HspBP1 is a novel protein that interacts with and inhibits Hsp70/Hsc70 chaperone activity.
  • Tumor cells often exhibit resistance to anticancer drugs, partly due to chaperone protein functions.

Purpose:

  • To investigate the effect of HspBP1 overexpression on the apoptotic response of tumor cells to anticancer drugs.
  • To determine the specific region of HspBP1 responsible for its interaction with Hsp70/Hsc70 and its functional consequences.

Summary:

  • HspBP1 was identified as an inhibitor of Hsp70/Hsc70 chaperone activity.
  • Overexpression of HspBP1 enhanced drug-induced apoptosis in tumor cells.
  • The C-terminal 47 amino acid residues of HspBP1 are essential for its interaction with Hsp70/Hsc70 and its ability to enhance apoptosis.

Impact:

  • These findings indicate that inhibiting Hsp70 chaperone function can enhance the therapeutic efficacy of chemotherapy.
  • HspBP1 represents a potential target for modulating cancer treatment outcomes.
  • Understanding HspBP1-Hsp70 interactions provides insights into novel strategies for overcoming drug resistance in cancer therapy.

More Related Videos

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...